NFKB1 and acute myeloid leukemia: Direct inhibition of NFκB is achieved by interaction with the glucocorticoid receptor: glucocorticoids indeed have shown activity both against chemoresistant AML cells and also as a clinical treatment for hyperleukocytosis in AML, which is characterized by massive entry of leukemic blasts in peripheral blood [127,128,129].